Ticker

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the FDA has accepted the supplemental New Drug Application (sNDA) for nebulized Tyvaso® (treprostinil) Inhalation Solution to treat IPF. United Therapeutics anticipates the agency's review to be complete in late April 2027. Nebulized Tyvaso has not…

Canada Pension Plan Investment Board bought a new position in United Therapeutics Corporation (NASDAQ: UTHR) in the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 6,200 shares of the biotechnology company's stock, valued at approximately $3,359,000. A number of other institutional investors and hedge

Freestone Grove Partners LP bought a new position in United Therapeutics Corporation (NASDAQ: UTHR) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 1,207 shares of the biotechnology company's stock, valued at approximately $654,000. A number of other large investors have also

Corient Private Wealth LP purchased a new stake in United Therapeutics Corporation (NASDAQ: UTHR) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 15,582 shares of the biotechnology company's stock, valued at approximately $8,443,000. Other institutional investors and hedge funds also recently

UTHR's ralinepag NDA receives FDA acceptance, with a 2027 decision ahead as positive phase III data support its PAH potential.